SELLAS’ cancer programs target diverse indications in hematological cancers and solid tumors.

learn more


The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute as a top priority target for immunotherapy.

learn more


SELLAS’ therapies have the potential to treat 20+ cancers characterized by an overexpression of the WT1 antigen.

learn more

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The Company’s lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. In January 2020, GPS entered a pivotal Phase 3 clinical trial in patients with AML.

Learn More

Latest News

Our Partnerships

SELLAS has an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center for its proprietary WT1 cancer immunotherapy, as well as partnerships with PolyPeptide Group and Corden Pharma.